Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin

Moore, Christopher; George, Magdalena; Thiel, David H. Van

doi:10.1007/s10620-011-1869-6

Cited by 3 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The approved dose of CIFN varies from country to country; for instance, in the United States, the approved dose is 15 μg three times a week given subcutaneously, whereas in Germany it is 9 µg three times a week (3, 17, 32). To provide more favorable kinetics and subsequent maximal viral suppression, a daily dosing trial was attempted (17, 33, 34). However, in DIRECT trial, a daily dose of 15 µg was found to be associated with discontinuation of CIFN in 21% patients due to various side effects (33).…”

Section: Discussionmentioning

confidence: 99%

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

et al. 2013

View full text Add to dashboard Cite

BackgroundNot enough data are available about the effectiveness of consensus interferon (CIFN) among HCV genotype 3 patients who failed to respond to pegylated interferon and ribavirin.ObjectivesWe aimed to assess the efficacy and safety of CIFN and ribavirin in non-responders and relapsers to pegylated interferon with ribavirin therapy.Patients and MethodsThis open-label investigator-initiated study included 44 patients who received CIFN 15 µg /day plus ribavirin 800-1200 mg daily. In patients with an early virological response (EVR), the dose of CIFN was reduced to 15 µg thrice a week for further 36 weeks. Patients with delayed virological response continued to receive daily CIFN plus ribavirin to complete 48 weeks. The patients were considered “non-responders” if there were less than 2 log reduction in HCV RNA at 12 weeks and detectable HCV RNA at 24 weeks.ResultsTwenty-four patients (55%) were non-responders and 20 patients were relapsers to the previous treatment with pegylated interferon plus ribavirin (mean age 43.6 ± 9.4 years, males 25 (57%)). Nine patients were clinically cirrhotic (Child A). End of treatment virological response was achieved in 19 (43.1%) patients and sustained virological response (SVR) occurred in 12 (27.3%). Out of these 12 patients, eight were non-responders and four were relapsers to the previous treatment. Advanced fibrosis or clinical cirrhosis was associated with low SVR. Adverse events were fever, myalgia, anorexia, depression, and weight loss. Two patients received granulocyte colony stimulating factor for transient neutropenia. Seven patients were given erythropoietin to improve hemoglobin, and six were treated for mild depression. Two patients developed portosystemic encephalopathy.ConclusionsMore than one-quarter of treatment-experienced patients with HCV genotype 3 achieved SVR after re-treatment with consensus interferon plus ribavirin.

show abstract

Section: Discussionmentioning

confidence: 99%

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

et al. 2013

View full text Add to dashboard Cite

show abstract

“…However, its frequent dosing and similar side effect profile to PEG‐IFN‐α also make compliance challenging. Attempts to create a pegylated version of consensus IFN have been unsuccessful .…”

Section: Clinical Trials Of Alternative Interferons and Immunomodulatmentioning

confidence: 99%

Alternative interferons and immunomodulators in the treatment of hepatitis C

Alao

Liang

2013

Liver International

View full text Add to dashboard Cite

show abstract

“…CIFN shares an 89, 30, and 60% homology with IFN-α, IFN-β and IFN-ω, respectively (13). CIFN has been shown to be efficacious in HCV genotype 1 patients who have failed therapy with PEG-IFN (14). In order to increase the duration of action, recombinant human CIFN was PEG-modified (pegylated) by Chongqing Fujin Biomedical Co., Ltd. (Chongqing, China).…”

Section: Introductionmentioning

confidence: 99%

Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C

Ding

Liu

Zhang

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

This study aimed to explore and evaluate the tolerability and antiviral activity of pegylated recombinant human consensus interferon-α (PEG-CIFN) in adults with hepatitis C virus (HCV) infection. A total of 48 adult subjects chronically infected with HCV were divided into five groups, which were treated separately with PEG-CIFN 1.0 µg/kg (n=10), 1.5 µg/kg (n=10), 2.0 µg/kg (n=9) or 3.0 µg/kg (n=10), or pegylated IFN α-2a (Pegasys) 180 µg (n=9) as controls. Symptoms were observed and laboratory results collected to monitor adverse reactions, adjust drug dosage and evaluate tolerability. The thrombocytopenic effects in all PEG-CIFN dose groups were less than that of pegylated IFN α-2a (at week 14, P<0.05). The rapid virologic response of the PEG-CIFN 1.5, 2.0 and 3.0 µg/kg groups and the pegylated IFN α-2a group were significantly higher than that of the PEG-CIFN 1.0 µg/kg group (P<0.05). Patients who had HCV genotype 1b infections had relatively high responses. The early virologic response of the PEG-CIFN 1.0, 1.5 and 2.0 µg/kg groups and the pegylated IFN α-2a group were 30, 90, 88.8 and 88.8% respectively. PEG-CIFN is well tolerated, and was found to have dose-dependent effectiveness in subjects with chronic hepatitis C. Virological response rates between PEG-CIFN 1.5 or 2.0 µg/kg, and pegylated IFNα-2a were similar, and not significantly different. It is concluded that 1.5 µg/kg PEG-CIFN may be the clinically recommended dose. PEG-CIFN is superior to pegylated IFN α-2a in maintaining platelet levels.

show abstract

Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin

Cited by 3 publications

References 38 publications

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

Alternative interferons and immunomodulators in the treatment of hepatitis C

Tolerability and efficacy of pegylated consensus interferon-α in the treatment of chronic hepatitis C

Contact Info

Product

Resources

About